Key Highlights
- GSK plc (LSE:GSK) shares fell 2.02% on Thursday, 1 October 2026, extending recent weakness.
- The stock had already dropped around 2.6% over the previous seven trading days.
- Surging gilt and Treasury yields pressured defensive and long-duration healthcare stocks.
- GSK agreed to acquire a trispecific T-cell engager from Chimagen in September as it builds its oncology pipeline.
- Broker opinion remains split, with Berenberg upgrading to buy while Barclays reiterated a sell rating.
GSK plc (LSE:GSK) Extends Pullback
GSK plc (LSE:GSK), the British pharmaceutical and vaccines group, closed 2.02% lower on Thursday, adding to losses from the previous week. The shares had fallen roughly 2.6% over the seven trading days to 30 September, although they remained modestly higher year to date and had delivered a total Shareholder return of more than 20% over the past year.
The FTSE 100 dropped 1.68% to 10,428.27 on Thursday, with even defensive sectors such as pharmaceuticals unable to escape the Bond Market sell-off.
Why GSK Shares Fell Today
The dominant driver was the global rise in bond yields. The 30-year gilt yield hit 6%, its highest since 1998, while the US 10-year Treasury Yield rose to about 5.34%. Pharmaceutical companies are typically valued on long-term cash flows from drug portfolios and pipelines, so higher discount rates reduce the present value of those future earnings.
Large pharma stocks are also widely owned as defensive, dividend-paying holdings. When bonds offer yields of 5% to 6%, some income investors reduce exposure to these equities.
GSK plc (LSE:GSK) earns a large share of its Revenue in the United States, and ongoing debates around US drug pricing, as well as the effects of an earlier pricing agreement with the US administration, continue to influence sentiment. A stronger dollar outlook from rising US yields can also create currency translation effects for UK-listed drugmakers.
Why GSK Is in Focus
GSK has been building its pipeline aggressively, especially in oncology. In September, it agreed to acquire a trispecific T-cell engager programme from Chimagen, adding to a series of Business development moves aimed at strengthening growth beyond the end of the decade. The company has also been pursuing cost-saving restructuring in its vaccines business.
Investors are focused on how GSK will offset the loss of exclusivity on its key HIV medicine dolutegravir later this decade. The group has guided that revenue growth will slow this year as it navigates Patent expiries and US pricing changes.
Broker views are divided. Berenberg upgraded the stock to buy in mid-September, while Barclays has repeatedly reiterated a sell rating and RBC Capital holds a neutral view. Some analysts argue growth to 2030 looks muted, while others see value in the pipeline. GSK has also extended funding for tuberculosis research collaborations, keeping its global health work in focus.
What Investors Are Watching Next
Third-quarter results, expected in late October, will be key for sales trends in specialty medicines, vaccines performance, Margin guidance and pipeline updates. Clinical trial readouts in oncology and respiratory medicines will also be closely monitored.
In the short term, bond yields and Friday's US jobs report will continue to influence defensive healthcare stocks.
Investor Takeaway
The 2.02% fall in GSK plc (LSE:GSK) reflects rate-driven pressure on the pharma sector. Pipeline building and upcoming results will determine whether investors view the recent dip as an opportunity.






Please wait processing your request...